Galactose-1-Phosphate Uridyltransferase Deficiency - An Overview

Introduction

Galactosemia is a metabolic disorder that occurs naturally as a result of poor galactose breakdown. Within days of delivery, afflicted newborns may have severe morbidity if diagnosis and treatment are delayed. In affluent nations, newborn screening programs have made identifying afflicted babies at an early age easier. Though feeding intolerance, hepatomegaly (enlarged liver), lethargy (feeling of being tired), coagulopathy (it is a disorder where there is a decrease in the blood's capacity to coagulate), and renal dysfunction can all develop in the first few days of life, even before newborn screening tests are finalized, healthcare practitioners must retain a high index of suspicion in sick babies.

What Pathophysiology Is Associated With Galactose-1-Phosphate Uridyltransferase Deficiency?

Lactose, a disaccharide included in breastfeeding and most infant formulae, is broken down into glucose and galactose, which are monosaccharides. The insufficiency of some enzymes in galactosemia prevents further metabolism of galactose. Although defects in galactose-1-phosphate uridylyltransferase (GALT) induce classic galactosemia, deficiencies in galactokinase and UDP-galactose epimerase might have comparable clinical effects by interfering with the normal metabolism of galactose. Finally, galactose can be converted to galactitol, the sugar alcohol form, if quantities of galactose-1-phosphate become hazardous. Galactitol is hypothesized to directly harm tissues, resulting in cataracts (it describes hazy vision caused by a lens opaquing, hepatomegaly (the term refers to the enlarged liver), cirrhosis, food intolerance, hypoglycemia (the term refers to a low blood sugar level), seizures (it is an abrupt, uncontrollable spike in brain electrical activity), lethargy, and intellectual disability. If left untreated, at least 75 percent of people die. Even with early treatment, consequences could include poor mood, trouble speaking, and behavioral or cognitive impairment. Even with early treatment, most girls will likely experience primary ovarian insufficiency or failure, speech issues, low bone mineral density, ataxia or tremors, and cognitive or behavioral impairment.

What Causes Galactose-1-Phosphate Uridyltransferase Deficiency?

The uridylyltransferase that catalyzes the conversion of galactose-1-phosphate to UDP-galactose is encoded by the GALT gene on chromosome 9p13. Galactosemia classica is caused by an enzyme deficiency. The enzyme galactokinase, which converts galactose to galactose-1-phosphate, is encoded by the GALK1 gene on chromosome 17q24. Chromosome 1p36-p35 has the GALE gene, which codes for UDP-galactose 4-epimerase. This enzyme converts UDP-galactose to UDP-glucose, which is then utilized in the glycogenesis (process of formation of glucose) process. Due to the autosomal recessive nature of inheritance, both parents must be carriers. The likelihood of clinical signs in kids is 25 percent. Usually, carriers show no symptoms at all.

A variation of galactosemia known as Duarte galactosemia is caused by decreased activity of the galactose-1-phosphate uridylyltransferase enzyme (usually between 14 and 25 percent). Without dietary intervention, people with Duarte variant galactosemia are generally regarded to be asymptomatic, and medical authorities agree that therapy is not necessary for those who are affected. There are, however, some reports that contradict this, and no sufficiently powered study has been done to confirm or deny the potential impact of reduced GALT activity on long-term neurodevelopmental outcomes. Newborn screening tests may or may not identify Duarte galactosemia.

What Signs and Symptoms Associated With Galactose-1-Phosphate Uridyltransferase Deficiency?

The build-up of precursor metabolites resulting from the insufficient activity of galactose 1-phosphate uridylyltransferase (GALT) in children who are not detected or treated can cause infections, bleeding, liver damage, and difficulties with feeding. Prolonged jaundice is frequently the first sign that a newborn presents with. If galactose restriction is not implemented, neonates may experience hyperammonemia (increased level of ammonia in blood), sepsis, and potentially even shock. Cataracts that resemble those observed in galactokinase deficiency might result from galectin accumulation and osmotic swelling. If galactose intake is sustained, long-term effects may include motor abnormalities, developmental verbal dyspraxia (a speech disorder), and developmental delays. Regardless of treatment, such as galactose restriction, galactosemic females often have ovarian failure.

What Is the Toxicokinetics of Increased Level of Galactose-1-Phosphate Uridyltransferase?

It is believed that alternate metabolism and direct tissue injury result from elevated levels of galactose-1-phosphate brought on by obstruction of the usual metabolic pathway. Patients with galactosemia have elevated levels of galactitol, or glucose converted to its sugar alcohol form, in their urine and tissues that show signs of damage from the disease. In addition to oxidizing to galactonate, galactose can also build into galactitol, which may be a more hazardous metabolite.

What Is the Treatment Plan for Galactose-1-Phosphate Uridyltransferase Deficiency?

GALT deficiency has no known cure; treatment is a lifelong galactose-free diet for the most badly afflicted patients. Patients do better when a modified diet is identified early on and put into practice. The amount of leftover GALT enzyme activity dictates how much food is restricted. Patients with greater residual enzyme activity levels usually tolerate greater amounts of galactose in the diet. Dietary restrictions are often eased as patients age. The therapy of patients with galactosemia in adulthood remains unclear despite the rise in patient identification and bettering patient outcomes.

Following diagnosis, patients are frequently given calcium and vitamin D3 supplements. It is unclear how the illness may develop over time in terms of growth delays, ataxia, and female ovarian failure. Patients with GALT deficiency are routinely monitored for the presence of cataracts with an ophthalmologic examination, speech assessment (if developmental verbal dyspraxia is evident), and measurements of metabolite levels (galactose 1-phosphate in red blood cells and galactitol in urine) to assess the efficacy and adherence to dietary therapy.

Conclusion

The most prevalent kind of galactosemia is known as galactose-1-phosphate uridylyltransferase deficiency or classic galactosemia. It is an inborn disorder in galactose metabolism brought on by a lack of the enzyme galactose-1-phosphate uridylyltransferase. If left untreated, this autosomal recessive metabolic abnormality can result in liver damage and even death. The best results from treating galactosemia are starting treatment early and limiting lactose in the diet. Galactosemia is included in newborn screening programs in many places since early intervention is crucial. During initial screening, which often entails determining the blood galactose concentration, galactokinase deficiency, galactose epimerase deficiency, and other inborn defects of galactose metabolism may be confused with classic galactosemia.